These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1367 related articles for article (PubMed ID: 28595656)
41. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
43. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in Wu PK; Hong SK; Park JI Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184 [TBL] [Abstract][Full Text] [Related]
44. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202 [TBL] [Abstract][Full Text] [Related]
45. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196 [TBL] [Abstract][Full Text] [Related]
46. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755 [TBL] [Abstract][Full Text] [Related]
48. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma. Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550 [TBL] [Abstract][Full Text] [Related]
49. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024 [TBL] [Abstract][Full Text] [Related]
50. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
51. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951 [TBL] [Abstract][Full Text] [Related]
52. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia. Bezić J; Tomić I; Pavić M Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192 [TBL] [Abstract][Full Text] [Related]
53. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712 [TBL] [Abstract][Full Text] [Related]
54. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Sabbatino F; Wang Y; Wang X; Flaherty KT; Yu L; Pepin D; Scognamiglio G; Pepe S; Kirkwood JM; Cooper ZA; Frederick DT; Wargo JA; Ferrone S; Ferrone CR Oncotarget; 2014 Apr; 5(7):1926-41. PubMed ID: 24732172 [TBL] [Abstract][Full Text] [Related]
55. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837 [TBL] [Abstract][Full Text] [Related]
56. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]
57. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Whittaker SR; Theurillat JP; Van Allen E; Wagle N; Hsiao J; Cowley GS; Schadendorf D; Root DE; Garraway LA Cancer Discov; 2013 Mar; 3(3):350-62. PubMed ID: 23288408 [TBL] [Abstract][Full Text] [Related]
58. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells. Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799 [TBL] [Abstract][Full Text] [Related]